Literature DB >> 21802387

Increased ACE in extrahepatic cholangiocarcinoma as a clue for activated RAS in biliary neoplasms.

Yavuz Beyazit1, Tugrul Purnak, Burak Suvak, Mevlut Kurt, Abdurrahim Sayilir, Turan Turhan, Adnan Tas, Serkan Torun, Tugrul Celik, Mehmet Ibis, Ibrahim C Haznedaroglu.   

Abstract

AIM: Cholangiocarcinoma (CCA) is a primary neoplastic tumor of the epithelial lining of the biliary tree which carries a poor prognosis despite combined therapeutic strategies. Although the exact etiology remains obscure, it has been suggested that locally produced Angiotensin II (Ang II) in intrahepatic CCA tissues plays a key role in the proliferation and activation of CCA. In the present study, we aimed to analyze the relationship between the levels of circulating angiotensin converting enzyme (ACE), an important molecule of the renin-angiotensin system (RAS), and biliary disorders. PATIENTS AND METHODS: The study group comprised 19 extrahepatic cholangiocarcinoma (EHCC) (16 patients with hilar, three patients with distal CCA), and 15 choledocolithiasis (CL) patients, with 15 controls. Median age of EHCC, CL and healthy controls were 67 (48-82), 65 (29-87) and 56 (23-74) respectively. ACE was measured by monitoring the alteration in absorbance at 340 nm of the hydrolysis of furylacrylolylphenylalanylglycylglycine (FAPGG) to FAP and GG on an analyzer. The ACE activity in the sample was determined by comparing the sample reaction rate to that obtained with the ACE calibrator.
RESULTS: Serum mean ACE levels were 56.6±27.4 U/L, 32.9±14.6 U/L and 28.6±10.6 U/L for patients with EHCC, CL and healthy controls, respectively. Serum ACE levels were significantly higher in patients with EHCC compared to CL and control groups. No significant differences with respect to ACE levels were observed between CL and control groups.
CONCLUSION: Circulating ACE in the context of RAS might be associated with EHCC development by creating a local environment enriched with cytokines and other growth factors that may promote cholangiocyte turnover.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21802387     DOI: 10.1016/j.clinre.2011.06.008

Source DB:  PubMed          Journal:  Clin Res Hepatol Gastroenterol        ISSN: 2210-7401            Impact factor:   2.947


  5 in total

1.  MDACT: A New Principle of Adjunctive Cancer Treatment Using Combinations of Multiple Repurposed Drugs, with an Example Regimen.

Authors:  Richard E Kast; Alex Alfieri; Hazem I Assi; Terry C Burns; Ashraf M Elyamany; Maria Gonzalez-Cao; Georg Karpel-Massler; Christine Marosi; Michael E Salacz; Iacopo Sardi; Pieter Van Vlierberghe; Mohamed S Zaghloul; Marc-Eric Halatsch
Journal:  Cancers (Basel)       Date:  2022-05-23       Impact factor: 6.575

2.  The roles of beta-adrenergic receptors in tumorigenesis and the possible use of beta-adrenergic blockers for cancer treatment: possible genetic and cell-signaling mechanisms.

Authors:  Khanh Vinh Quốc Lu'o'ng; Lan Thi Hoàng Nguyễn
Journal:  Cancer Manag Res       Date:  2012-12-18       Impact factor: 3.989

3.  Diagnostic and prognostic serum marker of cholangiocarcinoma (Review).

Authors:  Xiaojun Zeng; Hualin Tao
Journal:  Oncol Lett       Date:  2014-11-10       Impact factor: 2.967

Review 4.  Do renin-angiotensin system inhibitors influence the recurrence, metastasis, and survival in cancer patients?: Evidence from a meta-analysis including 55 studies.

Authors:  Hong Sun; Tao Li; Rongyuan Zhuang; Weimin Cai; Yuanting Zheng
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

5.  Comprehensive landscape of the renin-angiotensin system in Pan-cancer: a potential downstream mediated mechanism of SARS-CoV-2.

Authors:  Yuqing Cui; Fengzhi Chen; Jiayi Gao; Mengxia Lei; Dandan Wang; Xiaoying Jin; Yan Guo; Liying Shan; Xuesong Chen
Journal:  Int J Biol Sci       Date:  2021-09-03       Impact factor: 6.580

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.